Amphastar P (AMPH)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.25B
Last updated: Nov 17, 2026 at 11:05 AM ET
Amphastar P (AMPH) Earnings: Report Dates and Results
Amphastar P (AMPH) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Amphastar P reported EPS of $1.01, above the $0.80 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
AMPH has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 29.5% above the $0.61 reported for the quarter ended Dec 31, 2025.
AMPH Earnings Call
The latest AMPH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, AMPH beat 30, missed 9 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $207.61M, up 8.2% from $191.84M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $1.01 | $0.80 | $0.70 - $1.05 | +26.25% | Beat | +8.6% | 7 | 0 up, 1 down | Nov 5, 2026 | $207.61M |
| Jun 30, 2026 | $0.80 | $0.51 | $0.42 - $0.74 | +56.86% | Beat | +6.7% | 7 | 0 up, 3 down | Aug 6, 2026 | $183.90M |
| Mar 31, 2026 | $0.42 | $0.71 | $0.54 - $0.78 | -40.85% | Miss | -43.2% | 7 | 1 up, 2 down | May 7, 2026 | $171.17M |
| Dec 31, 2025 | $0.61 | $0.89 | $0.80 - $0.99 | -31.46% | Miss | -33.7% | 6 | 0 up, 1 down | Feb 26, 2026 | $183.10M |
| Sep 30, 2025 | $0.93 | $0.83 | $0.65 - $0.97 | +12.05% | Beat | -3.1% | 6 | 1 up, 3 down | Nov 6, 2025 | $191.84M |
| Jun 30, 2025 | $0.75 | $0.64 | $0.61 - $0.82 | +17.19% | Beat | -20.2% | 6 | 1 up, 1 down | Aug 7, 2025 | $174.41M |
| Mar 31, 2025 | $0.74 | $0.69 | $0.58 - $0.76 | +7.25% | Beat | -28.8% | 6 | 1 up, 0 down | May 7, 2025 | $170.53M |
| Dec 31, 2024 | $0.92 | $0.94 | $0.87 - $1.16 | -1.95% | Miss | +4.5% | 6 | 2 up, 2 down | Feb 27, 2025 | $186.52M |
| Sep 30, 2024 | $0.96 | $0.98 | $0.89 - $1.13 | -2.04% | Miss | -16.5% | 5 | 0 up, 0 down | Nov 6, 2024 | $191.21M |
| Jun 30, 2024 | $0.94 | $0.75 | $0.71 - $0.89 | +25.33% | Beat | +44.6% | 6 | 0 up, 0 down | Aug 7, 2024 | $182.39M |
| Mar 31, 2024 | $1.04 | $0.79 | $0.74 - $1.04 | +31.65% | Beat | +67.7% | 6 | 5 up, 0 down | May 8, 2024 | $171.84M |
| Dec 31, 2023 | $0.88 | $0.91 | $0.75 - $1.00 | -3.30% | Miss | +20.5% | 5 | 0 up, 0 down | Feb 28, 2024 | $178.10M |
| Sep 30, 2023 | $1.15 | $0.69 | $0.58 - $0.82 | +66.67% | Beat | +202.6% | 4 | 0 up, 0 down | Nov 8, 2023 | $180.56M |
| Jun 30, 2023 | $0.65 | $0.56 | $0.52 - $0.62 | +16.07% | Beat | +66.7% | 4 | 1 up, 0 down | Aug 8, 2023 | $145.71M |
| Mar 31, 2023 | $0.62 | $0.50 | $0.43 - $0.54 | +24.00% | Beat | +31.9% | 5 | 0 up, 0 down | May 9, 2023 | $140.02M |
| Dec 31, 2022 | $0.73 | $0.41 | $0.37 - $0.44 | +78.05% | Beat | +73.8% | 5 | 0 up, 0 down | Feb 28, 2023 | $135.02M |
| Sep 30, 2022 | $0.38 | $0.39 | $0.35 - $0.42 | -2.56% | Miss | -17.4% | 6 | 0 up, 0 down | Nov 7, 2022 | $120.13M |
| Jun 30, 2022 | $0.39 | $0.35 | $0.30 - $0.40 | +11.43% | Beat | +85.7% | 5 | 0 up, 0 down | Aug 8, 2022 | $123.47M |
| Mar 31, 2022 | $0.47 | $0.36 | $0.29 - $0.39 | +30.56% | Beat | +74.1% | 6 | 1 up, 0 down | May 9, 2022 | $120.37M |
| Dec 31, 2021 | $0.42 | $0.36 | $0.33 - $0.51 | +16.67% | Beat | +162.5% | 6 | 0 up, 0 down | Mar 10, 2022 | $120.89M |
| Sep 30, 2021 | $0.46 | $0.23 | $0.22 - $0.29 | +100.00% | Beat | +206.7% | 6 | N/A | Nov 8, 2021 | $112.20M |
| Jun 30, 2021 | $0.21 | $0.21 | $0.17 - $0.28 | 0.00% | In line | +31.2% | 6 | N/A | Aug 9, 2021 | $101.66M |
| Mar 31, 2021 | $0.27 | $0.18 | $0.15 - $0.25 | +50.00% | Beat | +58.8% | 7 | N/A | May 6, 2021 | $103.02M |
| Dec 31, 2020 | $0.16 | $0.14 | $0.12 - $0.15 | +14.29% | Beat | +128.6% | 7 | N/A | Mar 15, 2021 | $95.92M |
| Sep 30, 2020 | $0.15 | $0.14 | $0.12 - $0.17 | +7.14% | Beat | +50.0% | 7 | N/A | Nov 6, 2020 | $83.43M |
| Jun 30, 2020 | $0.16 | $0.14 | $0.10 - $0.20 | +14.29% | Beat | +100.0% | 7 | N/A | Aug 6, 2020 | $85.81M |
| Mar 31, 2020 | $0.17 | $0.09 | $0.07 - $0.12 | +88.89% | Beat | +70.0% | 6 | N/A | May 7, 2020 | $84.69M |
| Dec 31, 2019 | $0.07 | $0.08 | -$0.01 - $0.13 | -12.50% | Miss | -46.2% | 6 | N/A | Mar 12, 2020 | $83.38M |
| Sep 30, 2019 | $0.10 | $0.07 | $0.03 - $0.11 | +42.86% | Beat | -16.7% | 6 | N/A | Nov 7, 2019 | $80.14M |
| Jun 30, 2019 | $0.08 | $0.05 | -$0.05 - $0.08 | +60.00% | Beat | +166.7% | 6 | N/A | Aug 7, 2019 | $79.05M |
| Mar 31, 2019 | $0.10 | $0.05 | -$0.03 - $0.07 | +100.00% | Beat | N/A | 6 | N/A | May 9, 2019 | $79.79M |
| Dec 31, 2018 | $0.13 | $0.11 | $0.08 - $0.14 | +18.18% | Beat | +30.0% | 6 | N/A | Mar 12, 2019 | $89.69M |
| Sep 30, 2018 | $0.12 | $0.11 | $0.02 - $0.21 | +9.09% | Beat | +71.4% | 6 | N/A | Nov 8, 2018 | $75.54M |
| Jun 30, 2018 | $0.03 | $0.08 | $0.02 - $0.10 | -62.50% | Miss | -72.7% | 6 | N/A | Aug 8, 2018 | $71.04M |
| Mar 31, 2018 | -$0.05 | $0.08 | $0.04 - $0.12 | -162.50% | Miss | -155.6% | 6 | N/A | May 9, 2018 | $58.39M |
| Dec 31, 2017 | $0.10 | -$0.02 | -$0.30 - $0.10 | +600.00% | Beat | +900.0% | 6 | N/A | Mar 12, 2018 | $60.40M |
| Sep 30, 2017 | $0.07 | $0.03 | N/A | +133.33% | Beat | -50.0% | N/A | N/A | Nov 8, 2017 | $57.92M |
| Jun 30, 2017 | $0.11 | $0.07 | N/A | +57.14% | Beat | -52.2% | N/A | N/A | Aug 9, 2017 | $65.19M |
| Mar 31, 2017 | $0.09 | $0.08 | N/A | +12.50% | Beat | -25.0% | N/A | N/A | May 8, 2017 | $56.67M |
| Dec 31, 2016 | $0.01 | -$0.01 | N/A | +200.00% | Beat | -94.7% | N/A | N/A | Mar 13, 2017 | $63.54M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $3.03, down 21.5% from the year before. It was $0.50 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $3.03 | -21.5% |
| Dec 31, 2024 | $3.86 | +17.0% |
| Dec 31, 2023 | $3.30 | +67.5% |
| Dec 31, 2022 | $1.97 | +44.9% |
| Dec 31, 2021 | $1.36 | +112.5% |
| Dec 31, 2020 | $0.64 | +82.9% |
| Dec 31, 2019 | $0.35 | +52.2% |
| Dec 31, 2018 | $0.23 | -37.8% |
| Dec 31, 2017 | $0.37 | -26.0% |
| Dec 31, 2016 | $0.50 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,600 words across 11 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,600 | 11 | |
| 2026Q2 | Jun 30, 2026 | 4,010 | 10 | |
| 2026Q1 | Mar 31, 2026 | 3,289 | 8 | |
| 2025Q4 | Dec 31, 2025 | 3,381 | 8 | |
| 2025Q3 | Sep 30, 2025 | 3,678 | 10 | |
| 2025Q2 | Jun 30, 2025 | 2,755 | 9 | |
| 2025Q1 | Mar 31, 2025 | 4,250 | 9 | |
| 2024Q4 | Dec 31, 2024 | 3,286 | 9 |
2026Q3 Earnings Call
Opening remarks
Dan Dischner Senior Vice President of Corporate Communications Thank you, Paul. Good afternoon, everyone, and thank you for joining Amphastar's third quarter 2026 earnings call. Earlier today, we reported our financial results for the third quarter ended September 30th, 2026, which are available on the Investors page of our website. The third quarter was marked by record commercial performance, continued progress on our IMS remediation efforts, and further advancements of our development pipeline. We achieved quarterly revenue of $207.6 million, up approximately 8% year-over-year and 13% sequentially. Growth was driven primarily by strong performance from BAQSIMI and Primatene MIST, supplemented by contributions from recently launched products. Gross margin decreased during the quarter, primarily driven by the impact of lower net pricing on certain products and higher manufacturing expenses, including costs associated with the remediation efforts at our IMS manufacturing facility. Bill will provide additional detail on these factors as well as the year-over-year earnings comparison in the financial review. Our strategy remains focused on three complementary growth priorities. First, maximizing the growth of BAQSIMI and Primatene MIST while expanding our differentiated commercial portfolio. Second, advancing our pipeline of complex generics and biosimilars. And third, progressing our proprietary development program. Our scientific, manufacturing, and commercial capabilities support each of these initiatives. I would like to provide an update on each, beginning with our commercial portfolio. BAQSIMI delivered record quarterly net sales of $58.8 million, representing growth of approximately 10% compared to the prior year's period. The increase was driven by higher unit volumes, partially offset by lower net pricing associated with commercial discounts and customer mix. During the quarter, the measures we implemented to address duplicate 340B discounts continued to produce results, further reducing their impact relative to the second quarter. We remain focused on driving prescription growth, expanding patient access, and executing our commercial strategy to maximize the long-term value of the franchise. Primatene MIST delivered record quarterly net sales of $31.5 million, an increase of approximately 9% compared to the prior year's period. Growth was driven by both the price increase implemented in the second quarter and higher unit volumes, with in-store unit sales increasing approximately 2.5% year-over-year. These results highlighted the strength of our commercial operation and our ability to successfully manage differentiated pharmaceutical products across multiple markets and distribution channels. More recent product launches also contributed meaningfully during the quarter. Specifically, ipratropium bromide, which launched in April, generated $6.6 million in sales, while teriparatide contributed $6.4 million. These launches supported overall portfolio growth and partially offset headwinds affecting certain established products, including glucagon injections.
Frequently Asked Questions About AMPH
When is Amphastar P's next earnings date?
Amphastar P's next earnings report is expected for Feb 24, 2027.
Did AMPH beat earnings estimates last quarter?
Yes. Amphastar P reported EPS of $1.01 for the quarter ended Sep 30, 2026, above the $0.80 estimate, a 26.25% surprise.
What EPS do analysts expect from AMPH next quarter?
The consensus EPS estimate for Amphastar P for the quarter ending Dec 31, 2026 is $0.79 from 9 analysts, with estimates from $0.51 to $1.05.
How often does AMPH beat earnings estimates?
Amphastar P beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +5.67%.
AMPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors